An examination of chimpanzee use in human cancer research

Alternatives to Laboratory Animals

Volumn 37, Issue 4, 2009, Pages 399-416

  Bailey, Jarrod ^a  

^a New England Anti Vivisection Society   (United States)

Author keywords

Cancer; Chimpanzee; Neoplasm; Pan troglodytes

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN; CETUXIMAB; CYTIDINE PHOSPHATE N ACYLNEURAMINATE PHOSPHODIESTERASE; DENDRITIC CELL VACCINE; DNA; DPC 333; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; INTERLEUKIN 2; ISOFLAVONOID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HA6D3; MUCIN 1; NOTCH RECEPTOR; PANITUMUMAB; RECOMBINANT INTERLEUKIN 2; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RITUXIMAB; SONIC HEDGEHOG PROTEIN; TGN 1412; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ADVANCED CANCER; ANIMAL MODEL; ANTIBODY RESPONSE; B LYMPHOCYTE; BLEEDING; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER RESEARCH; CANCER SUSCEPTIBILITY; CANCER THERAPY; CAUSE OF DEATH; CELL GROWTH; CELL RESPIRATION; CHIMPANZEE; CITATION ANALYSIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SAFETY; DRUG TARGETING; GENETIC DIFFERENCE; GENETIC SIMILARITY; GENETIC VARIABILITY; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS; HUMAN VERSUS ANIMAL COMPARISON; HYPERTENSION; IMMUNITY; IMMUNOGENICITY; KIDNEY CARCINOMA; MEDLINE; MELANOMA; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RNA SPLICING; T CELL LEUKEMIA; T LYMPHOCYTE; THROMBOSIS; TUMOR GROWTH; TUMOR VIRUS;

PAN; PAN TROGLODYTES;

EID: 70449592349     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119290903700410     Document Type: Conference Paper

References (207)

1. Cohen, J. (2007). Biomedical research. The endangered lab chimp. Science, New York 315, 450-452.
2. NEAVS (2008). End Chimpanzee Research: An Overview - International Bans. Available at: http://www.releasechimps.org/mission/end- chimpanzee-research/ country-bans/ (Accessed 10. 06.09). Boston, MA, USA: New England Anti- Vivisection Society (Project R&R).
3. Vermij, P. (2003). Europe's last research chimps to retire. Nature Medicine 9, 981.
4. de Kok, W. (2002). Dutch Lab Chimps to be Retired. Available at: http://www.ippl.org/2002-dutch- chimps.php (Accessed 10.06.09). Summerville, SC, USA: International Primate Protection League.
5. NEAVS (2005). Public Opinion. Available at: http://www.releasechimps.org/ mission/end- chimpanzee-research/public-opinion/ (Accessed 10. 06.09). Boston, MA, USA: New England Anti- Vivisection Society (Project R&R).
6. VandeBerg, J.L. & Zola, S.M. (2005). A unique biomedical resource at risk. Nature, London 437, 30-32.
7. Bailey, J. & Balcombe, J. (2007). Chimpanzee Research: An Examination of its Contribution to Biomedical Knowledge and Efficacy in Combating Human Diseases, 47pp. Available at: http://www. releasechimps.org/pdfs/chimp-efficacy- paper- main.pdf (Accessed 10.06.09). Boston, MA, USA: New England Anti-Vivisection Society (Project R&R).
8. Knight, A. (2007). The poor contribution of chimpanzee experiments to biomedical progress. Journal of Applied Animal Welfare Science 10, 281-308.
9. Bailey, J. (2008). An assessment of the role of chimpanzees in AIDS vaccine research. ATLA 36, 381-428.
10. Bradshaw, G.A., Capaldo, T., Lindner, L. & Grow, G. (2008). Building an inner sanctuary: complex PTSD in chimpanzees. Journal of Trauma & Dissociation 9, 9-34.
11. Bradshaw, G.A., Capaldo, T., Lindner, L. & Grow, G. (2009). Developmental context effects on bi-cultural post-trauma self repair in chimpanzees. Developmental Psychology 45, in press.
12. Albreht, T., McKee, M., Alexe, D.M., Coleman, M.P. & Martin-Moreno, J.M. (2008). Making progress against cancer in Europe in 2008. European Journal of Cancer 44, 1451-1456.
13. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. & Thun, M.J. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians 58, 71-96.
14. Britten, R.J. (2002). Divergence between samples of chimpanzee and human DNA sequences is 5%, counting indels. Proceedings of the National Academy of Sciences of the USA 99, 13,633- 13,635.
15. Varki, A. & Altheide, T.K. (2005). Comparing the human and chimpanzee genomes: searching for needles in a haystack. Genome Research 15, 1746-1758. (Pubitemid 41780405)
16. Technische Universitat Dresden (2009). GoPubMed. Available at: http://www.gopubmed.com/ (Accessed 10.06.09). Dresden, Germany: Transinsight GmbH.
17. Toft 2nd, J.D. & MacKenzie, W.F. (1975). Endometrial stromal tumor in a chimpanzee. Veterinary Pathology 12, 32-36.
18. Chandler, F.W., McClure, H.M., Campbell, W.G. & Watts, J.C. (1976). Pulmonary pneumocystosis in nonhuman primates. Archives of Pathology & Laboratory Medicine 100, 163-167.
19. Graham, C.E. & McClure, H.M. (1976). Sertoli- Leydig cell tumor in a chimpanzee. Laboratory. Animal Science 26, 948-950.
20. Graham, C.E. & McClure, H.M. (1977). Ovarian tumors and related lesions in aged chimpanzees. Veterinary Pathology 14, 380-386.
21. Amyx, H.L., Salazar, A.M., Newsome, D.A., Gibbs, C.J.J. & Gajdusek, D.C. (1982). Nasopharyngeal carcinoma with intracranial extension in a chimpanzee. Journal of the American Veterinary Medical Association 181, 1425-1426.
22. Barriere, H., Litoux, P., Le Lay, M., Bureau, B., Stalder, J.F. & Dreno, B. (1984). [Cutaneous achromia and malignant melanoma]. Annales de Dermatologie et de Venereologic 111, 991-996.
23. Porter, B.F., Goens, S.D., Brasky, K.M. & Hubbard, G.B. (2004). A case report of hepatocellular carcinoma and focal nodular hyperplasia with a myelolipoma in two chimpanzees and a review of spontaneous hepatobiliary tumors in non-human primates. Journal of Medical Primatology 33, 38-47.
24. Muchmore, E., Popper, H., Peterson, D.A., Miller, M.F. & Lieberman, H.M. (1988). Non-A, non-B hepatitis-related hepatocellular carcinoma in a chimpanzee. Journal of Medical Primatology 17, 235-246. (Pubitemid 19010406)
25. Abe, K., Kagei, N., Teramura, Y. & Ejima, H. (1993). Hepatocellular carcinoma associated with chronic Schistosoma mansoni infection in a chimpanzee. Journal of Medical Primatology 22, 237-239.
26. Greenwood, A.G., Lowe, J.W. & Gaunt, L. (1995). Renal carcinoma in a chimpanzee (Pan troglodytes). Veterinary Record 137, 380-381.
27. Binhazim, A.A., Lee, D.R., Bernacky, B.J. & Rizvi, T.A. (1997). Spontaneous anaplastic large cell lymphoma in a chimpanzee: a clinicopathological and immunohistochemical study. Journal of Medical Primatology 26, 260-266.
28. Starost, M.F. & Martino, M. (2002). Adenoma of the gallbladder in a chimpanzee (Pan troglodytes). Journal of Zoo & Wildlife Medicine 33, 176-177. (Pubitemid 135715002)
29. Saturday, G.A., Lasota, J., Frost, D., Brasky, K.B., Hubbard, G. & Miettinen, M. (2005). KIT-positive gastrointestinal stromal tumor in a 22-year-old male chimpanzee (Pan troglodytes). Veterinary Pathology 42, 362-365. (Pubitemid 40704829)
30. Klopfleisch, R., Langner, C., von Felbert, I., Rudnick, J.C. & Teifke, J.P. (2007). Nevus lipo3 matosus cutaneus superficialis (Hoffmann- Zurhelle) in a chimpanzee (Pan troglodytes). Journal of Medical Primatology 36, 57-60. (Pubitemid 46443578)
31. Van Ranst, M., Fuse, A., Fiten, P., Beuken, E., Pfister, H., Burk, R.D. & Opdenakker, G. (1992). Human papillomavirus type 13 and pygmy chimpanzee papillomavirus type 1: comparison of the genome organizations. Virology 190, 587-596.
32. Thakral, D., Dobbins, J., Devine, L. & Kavathas, P.B. (2008). Differential expression of the human CD8beta splice variants and regulation of the M-2 isoform by ubiquitination. Journal of Immunology 180, 7431-7442.
33. Hedlund, M., Tangvoranuntakul, P., Takematsu, H., Long, J.M., Housley, G.D., Kozutsumi, Y., Suzuki, A., Wynshaw-Boris, A., Ryan, A.F., Gallo, R.L., Varki, N. & Varki, A. (2007). N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Molecular & Cellular Biology 27, 4340-4346.
34. Varki, A. (2001). Loss of N-glycolylneuraminic acid in humans: Mechanisms, consequences, and implications for hominid evolution. American Journal of Physical Anthropology Suppl. 33, 54-69. (Pubitemid 33610495)
35. Zhu, Q.Y., Liu, Y. & Zhu, N.S. (2007). [Molecular evolution of GAGE gene family]. Yi Chuan 29, 559-564.
36. Baysal, B.E., Lawrence, E.C. & Ferrell, R.E. (2007). Sequence variation in human succinate dehydrogenase genes: evidence for long-term balancing selection on SDHA. BMC Biology 5, 12.
37. Baysal, B.E., Ferrell, R.E., Willett-Brozick, J.E., Lawrence, E.C., Myssiorek, D., Bosch, A., van der Mey, A., Taschner, P.E., Rubinstein, W.S., Myers, E.N., Richard 3rd, C.W., Cornelisse, C.J., Devilee, P. & Devlin, B. (2000). Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, New York 287, 848-851.
38. Niemann, S. & Muller, U. (2000). Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature Genetics 26, 268-270. (Pubitemid 30824601)
39. Astuti, D., Latif, F., Dallol, A., Dahia, P.L., Douglas, F., George, E., Skoldberg, F., Husebye, E.S., Eng, C. & Maher, E.R. (2001). Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. American Journal of Human Genetics 69, 49-54. (Pubitemid 32614017)
40. Baysal, B.E., Willett-Brozick, J.E., Lawrence, E.C., Drovdlic, C.M., Savul, S.A., McLeod, D.R., Yee, H.A., Brackmann, D.E., Slattery 3rd, W.H., Myers, E.N., Ferrell, R.E. & Rubinstein, W.S. (2002). Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. Journal of Medical Genetics 39, 178-183.
41. Baysal, B.E., Willett-Brozick, J.E., Filho, P.A., Lawrence, E.C., Myers, E.N. & Ferrell, R.E. (2004). An Alu-mediated partial SDHC deletion causes familial and sporadic paraganglioma. Journal of Medical Genetics 41, 703-709.
42. Bayley, J.P., Devilee, P. & Taschner, P.E. (2005). The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency. BMC Medical Genetics 6, 39. (Pubitemid 41794081)
43. Schiavi, F., Boedeker, C.C., Bausch, B., Peczkowska, M., Gomez, C.F., Strassburg, T., Pawlu, C., Buchta, M., Salzmann, M., Hoffmann, M.M., Berlis, A., Brink, I., Cybulla, M., Muresan, M., Walter, M.A., Forrer, F., Valimaki, M., Kawecki, A., Szutkowski, Z., Schipper, J., Walz, M.K., Pigny, P., Bauters, C., Willet-Brozick, J.E., Baysal, B.E., Januszewicz, A., Eng, C., Opocher, G. & Neumann, H.P. (2005). Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. Journal of the American Medical Association 294, 2057-2063.
44. Muller, G.A., Heissig, F. & Engeland, K. (2007). Chimpanzee, orangutan, mouse, and human cell cycle promoters exempt CCAAT boxes and CHR elements from interspecies differences. Molecular Biology & Evolution 24, 814-826. (Pubitemid 46355805)
45. Fernando, H., Reszka, A.P., Huppert, J., Ladame, S., Rankin, S., Venkitaraman, A.R., Neidle, S. & Balasubramanian, S. (2006). A conserved quadruplex motif located in a transcription activation site of the human c-kit oncogene. Biochemistry 45, 7854-7860. (Pubitemid 44185502)
46. Chen, Y.T., Iseli, C., Venditti, C.A., Old, L.J., Simpson, A.J. & Jongeneel, C.V. (2006). Identification of a new cancer/testis gene family, CT47, among expressed multicopy genes on the human X chromosome. Genes Chromosomes & Cancer 45, 392-400.
47. Gilad, Y., Oshlack, A., Smyth, G.K., Speed, T.P. & White, K.P. (2006). Expression profiling in primates reveals a rapid evolution of human transcription factors. Nature, London 440, 242-245. (Pubitemid 43372105)
48. Puente, X.S., Velasco, G., Gutierrez-Fernandez, A., Bertranpetit, J., King, M.C. & Lopez-Otin, C. (2006). Comparative analysis of cancer genes in the human and chimpanzee genomes. BMC Genomics 7, 15. (Pubitemid 43308465)
49. McCutcheon, I.E., Hentschel, S.J., Fuller, G.N., Jin, W. & Cote, G.J. (2004). Expression of the splicing regulator polypyrimidine tract-binding protein in normal and neoplastic brain. Neurooncology 6, 9-14. (Pubitemid 38139633)
50. Romanelli, M.G., Lorenzi, P. & Morandi, C. (2005). Identification and analysis of the human neural polypyrimidine tract binding protein (nPTB) gene promoter region. Gene 356, 11-18. (Pubitemid 41175967)
51. Johne, R., Enderlein, D., Nieper, H. & Muller, H. (2005). Novel Polyomavirus detected in the feces of a chimpanzee by nested broad-spectrum PCR. Journal of Virology 79, 3883-3887. (Pubitemid 40327979)
52. Pavlicek, A., Noskov, V.N., Kouprina, N., Barrett, J.C., Jurka, J. & Larionov, V. (2004). Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition. Human Molecular Genetics 13, 2737-2751. (Pubitemid 39567284)
53. Huttley, G.A., Easteal, S., Southey, M.C., Tesoriero, A., Giles, G.G., McCredie, M.R., Hopper, J.L. & Venter, D.J. (2000). Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study. Nature Genetics 25, 410-413. (Pubitemid 32983432)
54. Nelson, P.N., Carnegie, P.R., Martin, J., Davari Ejtehadi, H., Hooley, P., Roden, D., Rowland-Jones, S., Warren, P., Astley, J. & Murray, P.G. (2003). Demystified. Human endogenous retroviruses. Molecular Pathology 56, 11-18.
55. Barbulescu, M., Turner, G., Seaman, M.I., Deinard, A.S., Kidd, K.K. & Lenz, J. (1999). Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. Current Biology 9, 861-868. (Pubitemid 29456003)
56. Tarzami, S.T., Kringstein, A.M., Conte, R.A. & Verma, R.S. (1997). Unique genomic sequences in human chromosome 16p are conserved in the great apes. Molecular & General Genetics 253, 512-514. (Pubitemid 27075740)
57. Thoraval, D., Asakawa, J., Kodaira, M., Chang, C., Radany, E., Kuick, R., Lamb, B., Richardson, B., Neel, J.V., Glover, T. & Hanash, S. (1996). A methylated human 9-kb repetitive sequence on acrocentric chromosomes is homologous to a subtelomeric repeat in chimpanzees. Proceedings of the National Academy of Sciences of the USA 93, 4442-4447. (Pubitemid 26146733)
58. Dumont, M., Frank, D., Moisan, A.M., Tranchant, M., Soucy, P., Breton, R., Labrie, F., Tavtigian, S.V. & Simard, J. (2004). Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2. Biochimica et Biophysica Acta 1679, 230-247. (Pubitemid 39195177)
59. Kulski, J.K., Lim, C.P., Dunn, D.S. & Bellgard, M. (2003). Genomic and phylogenetic analysis of the S100A7 (Psoriasin) gene duplications within the region of the S100 gene cluster on human chromosome 1q21. Journal of Molecular Evolution 56, 397-406.
60. Morgan, K., Conklin, D., Pawson, A.J., Sellar, R., Ott, T.R. & Millar, R.P. (2003). A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology 144, 423-436. (Pubitemid 36205212)
61. Darby, S., Stockley, J., Khan, M.M., Robson, C.N., Leung, H.Y. & Gnanapragasam, V.J. (2007). Expression of GnRH type II is regulated by the androgen receptor in prostate cancer. Endocrine- related Cancer 14, 613-624. (Pubitemid 350074051)
62. Zhang, J. & Rosenberg, H.F. (2002). Diversifying selection of the tumor-growth promoter angiogenin in primate evolution. Molecular Biology & Evolution 19, 438-445. (Pubitemid 34289419)
63. Sale, S., Sung, R., Shen, P., Yu, K., Wang, Y., Duran, G.E., Kim, J.H., Fojo, T., Oefner, P.J. & Sikic, B.I. (2002). Conservation of the class I beta- tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Molecular Cancer Therapeutics 1, 215-225.
64. Sinkovics, J.G. & Horvath, J.C. (1999). Kaposi's sarcoma: breeding ground of herpesviridae - A tour de force over viral evolution (review). International Journal of Oncology 14, 615-646.
65. Greensill, J., Sheldon, J.A., Murthy, K.K., Bessonette, J.S., Beer, B.E. & Schulz, T.F. (2000). A chimpanzee rhadinovirus sequence related to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8: increased detection after HIV-1 infection in the absence of disease. AIDS 14, F129-35.
66. Kiyosawa, K., Daemer, R.J., He, L.F., Bonino, F., Prozesky, O.W. & Purcell, R.H. (1985). The spectrum of complement-fixing antinuclear antibodies in patients with hepatocellular carcinoma. Hepatology 5, 548-555. (Pubitemid 15029722)
67. Gerber, P., Pritchett, R.F. & Kieff, E.D. (1976). Antigens and DNA of a chimpanzee agent related to Epstein-Barr virus. Journal of Virology 19, 1090-1099.
68. Gerber, P., Kalter, S.S., Schidlovsky, G., Peterson, W.D.J. & Daniel, M.D. (1977). Biologic and antigenic characteristics of Epstein-Barr virus-related Herpesviruses of chimpanzees and baboons. International Journal of Cancer 20, 448-459. (Pubitemid 8172027)
69. Smith, G.C., Helmke, R.J., Barker, S.T., Kalter, S.S. & Heberling, R.L. (1976). Oncornavirus-like particles in baboon type C virus-infected chimpanzee lung cells (SFRE:CL-1). Journal of the National Cancer Institute 56, 1059-1061.
70. Mulders, T.M., Bruning, P.F. & Bonfrer, J.M. (1990). Prostate-specific antigen (PSA). A tissue- specific and sensitive tumor marker. European Journal of Surgical Oncology 16, 37-41. (Pubitemid 20079461)
71. Karr, J.F., Kantor, J.A., Hand, P.H., Eggensperger, D.L. & Schlom, J. (1995). The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line. Cancer Research 55, 2455-2462.
72. Boyle, P., Lembach, K.J. & Wetzel, G.D. (1993). The B5 monoclonal human autoantibody binds to cell surface TNF alpha on human lymphoid cells and cell lines and appears to recognize a novel epitope. Cellular Immunology 152, 569-581. (Pubitemid 24040506)
73. Mocellin, S. & Nitti, D. (2008). TNF and cancer: the two sides of the coin. Frontiers in Bioscience 13, 2774-2783. (Pubitemid 351599716)
74. Sethi, G., Sung, B. & Aggarwal, B.B. (2008). TNF: a master switch for inflammation to cancer. Frontiers in Bioscience 13, 5094-5107. (Pubitemid 351599660)
75. Hundsberger, H., Verin, A., Wiesner, C., Pfluger, M., Dulebo, A., Schutt, W., Lasters, I., Mannel, D.N., Wendel, A. & Lucas, R. (2008). TNF: a moon- lighting protein at the interface between cancer and infection. Frontiers in Bioscience 13, 5374-5386.
76. Martinez, J., Dugaiczyk, L.J., Zielinski, R. & Dugaiczyk, A. (2001). Human genetic disorders, a phylogenetic perspective. Journal of Molecular Biology 308, 587-596.
77. Gibbons, R. & Dugaiczyk, A. (2005). Phylogenetic roots of Alu-mediated rearrangements leading to cancer. Genome 48, 160-167. (Pubitemid 40748025)
78. Hwu, H.R., Roberts, J.W., Davidson, E.H. & Britten, R.J. (1986). Insertion and/or deletion of many repeated DNA sequences in human and higher ape evolution. Proceedings of the National Academy of Sciences of the USA 83, 3875-3879.
79. Jurka, J., Krnjajic, M., Kapitonov, V.V., Stenger, J.E. & Kokhanyy, O. (2002). Active Alu elements are passed primarily through paternal germlines. Theoretical Population Biology 61, 519-530.
80. Liu, G., Zhao, S., Bailey, J.A., Sahinalp, S.C., Alkan, C., Tuzun, E., Green, E.D. & Eichler, E.E. (2003). Analysis of primate genomic variation reveals a repeat-driven expansion of the human genome. Genome Research 13, 358-368. (Pubitemid 36395393)
81. Gibbons, R., Dugaiczyk, L.J., Girke, T., Duistermars, B., Zielinski, R. & Dugaiczyk, A. (2004). Distinguishing humans from great apes with AluYb8 repeats. Journal of Molecular Biology 339, 721-729.
82. Katoh, M. & Katoh, M. (2007). Comparative integromics on non-canonical WNT or planar cell polarity signaling molecules: transcriptional mechanism of PTK7 in colorectal cancer and that of SEMA6A in undifferentiated ES cells. International Journal of Molecular Medicine 20, 405-409.
83. Katoh, M. & Katoh, M. (2007). Integrative genomic analyses on HES/HEY family: Notch- independent HESl, HES3 transcription in undifferentiated ES cells, and Notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in fetal tissues, adult tissues, or cancer. International Journal of Oncology 31, 461-466.
84. Katoh, M. & Katoh, M. (2007). Comparative integromics on JMJDlC gene encoding histone demethylase: conserved POU5F1 binding site elucidating mechanism of JMJDlC expression in undifferentiated ES cells and diffuse-type gastric cancer. International Journal of Oncology 31, 219-223.
85. Katoh, Y. & Katoh, M. (2007). Comparative genomics on PROM1 gene encoding stem cell marker CD133. International Journal of Molecular Medicine 19, 967-970.
86. Katoh, M. & Katoh, M. (2007). Conserved POU/OCT- and GATA-binding sites in 5′-flanking promoter region of mammalian WNT8B orthologs. International Journal of Oncology 30, 1273-1277.
87. Katoh, M. & Katoh, M. (2007). AP1- and NF- kappaB-binding sites conserved among mammalian WNT10B orthologs elucidate the TNFalpha- WNT10B signaling loop implicated in carcinogenesis and adipogenesis. International Journal of Molecular Medicine 19, 699-703.
88. Katoh, M. & Katoh, M. (2007). Comparative integromics on FZD7 orthologs: conserved binding sites for PU.1, SP1, CCAAT-box and TCF/LEF/ SOX transcription factors within 5′-promoter region of mammalian FZD7 orthologs. Inter national Journal of Molecular Medicine 19, 529-533.
89. Katoh, Y. & Katoh, M. (2007). Conserved POU- binding site linked to SP1-binding site within FZD5 promoter: Transcriptional mechanisms of FZD5 in undifferentiated human ES cells, fetal liver/spleen, adult colon, pancreatic islet, and diffuse-type gastric cancer. International Journal of Oncology 30, 751-755.
90. Katoh, M. & Katoh, M. (2007). STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review). International Journal of Molecular Medicine 19, 273-278.
91. Katoh, M. & Katoh, M. (2006). NUMB is a break of WNT-Notch signaling cycle. International Journal of Molecular Medicine 18, 517-521.
92. Katoh, Y. & Katoh, M. (2006). Canonical WNT signaling pathway and human AREG. International Journal of Molecular Medicine 17, 1163-1166.
93. Katoh, Y. & Katoh, M. (2006). Comparative integromics on Angiopoietin family members. International Journal of Molecular Medicine 17, 1145-1149.
94. Katoh, Y. & Katoh, M. (2006). Comparative integromics on VEGF family members. International Journal of Oncology 28, 1585-1589.
95. Katoh, Y. & Katoh, M. (2006). Comparative integromics on BMP/GDF family. International Journal of Molecular Medicine 17, 951-955.
96. Katoh, M. & Katoh, M. (2006). Comparative integromics on Eph family. International Journal of Oncology 28, 1243-1247.
97. Katoh, Y. & Katoh, M. (2006). Comparative integromics on Ephrin family. Oncology Reports 15, 1391-1395.
98. Katoh, M. & Katoh, M. (2006). Notch ligand, JAGl, is evolutionarily conserved target of canonical WNT signaling pathway in progenitor cells. International Journal of Molecular Medicine 17, 681-685.
99. Katoh, Y. & Katoh, M. (2006). FGF signaling inhibitor, SPRY4, is evolutionarily conserved target of WNT signaling pathway in progenitor cells. International Journal of Molecular Medicine 17, 529-532.
100. Katoh, Y. & Katoh, M. (2006). WNT antagonist, SFRPl, is Hedgehog signaling target. International Journal of Molecular Medicine 17, 171-175.
101. Katoh, Y. & Katoh, M. (2005). Comparative genomics on Sonic hedgehog orthologs. Oncology Reports 14, 1087-1090.
102. Maeda, N. & Kim, H.S. (1990). Three independent insertions of retrovirus-like sequences in the haptoglobin gene cluster of primates. Genomics 8, 671-683.
103. Bonner, T.I., O'Connell, C. & Cohen, M. (1982). Cloned endogenous retroviral sequences from human DNA. Proceedings of the National Academy of Sciences of the USA 79, 4709-4713.
104. Song, B., Javanbakht, H., Perron, M., Park, D.H., Stremlau, M. & Sodroski, J. (2005). Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. Journal of Virology 79, 3930-3937. (Pubitemid 40388333)
105. Brown, P., Nemo, G. & Gajdusek, D.C. (1978). Human foamy virus: further characterization, seroepidemiology, and relationship to chimpanzee foamy viruses. Journal of Infectious Diseases 137, 421-427. (Pubitemid 8327255)
106. Bieniasz, P.D., Weiss, R.A. & McClure, M.O. (1995). Cell cycle dependence of foamy retrovirus infection. Journal of Virology 69, 7295-7299.
107. Kayman, S.C., Wu, Z., Revesz, K., Chen, H., Kopelman, R. & Pinter, A. (1994). Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. Journal of Virology 68, 400-410. (Pubitemid 24974644)
108. Hahm, S.H., Yi, Y., Lee, D.K., Noh, M.J., Yun, L., Hwang, S. & Lee, K.H. (2004). Construction of retroviral vectors with enhanced efficiency of transgene expression. Journal of Virological Methods 121, 127-136. (Pubitemid 39295702)
109. Leendertz, F.H., Junglen, S., Boesch, C., Formenty, P., Couacy-Hymann, E., Courgnaud, V., Pauli, G. & Ellerbrok, H. (2004). High variety of different simian T-cell leukemia virus type 1 strains in chimpanzees (Pan troglodytes verus) of the Taï National Park, Côte d'Ivoire. Journal of Virology 78, 4352-4356. (Pubitemid 38437238)
110. Langlois, R.G., Bigbee, W.L. & Jensen, R.H. (1985). Flow cytometric characterization of normal and variant cells with monoclonal antibodies specific for glycophorin A. Journal of Immunology 134, 4009-4017.
111. Lindeskog, M., Medstrand, P., Cunningham, A.A. & Blomberg, J. (1998). Coamplification and dispersion of adjacent human endogenous retroviral HERV-H and HERV-E elements; presence of spliced hybrid transcripts in normal leukocytes. Virology 244, 219-229. (Pubitemid 28384140)
112. Alter, H.J., Eichberg, J.W., Masur, H., Saxinger, W.C., Gallo, R., Macher, A.M., Lane, H.C. & Fauci, A.S. (1984). Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science, New York 226, 549-552. (Pubitemid 14018527)
113. Zhou, E.M., Chanh, T.C., Dreesman, G.R., Kanda, P. & Kennedy, R.C. (1987). Immune response to human immunodeficiency virus. In vivo administration of anti-idiotype induces an anti-gp160 response specific for a synthetic peptide. Journal of Immunology 139, 2950-2956.
114. Dowell, B.L., Tuck, F.L., Borowitz, M.J., LeBien, T.W. & Metzgar, R.S. (1984). Phylogenetic distribution of a 24,000 dalton human leukemia-associated antigen on platelets and kidney cells. Developmental & Comparative Immunology 8, 187-195.
115. Lapin, B.A., Voevodin, A.F., Indzhiia, L.V., Iakovleva, L.I. & Gallo, R. (1983). [Etiological aspects of leukemias in primates including man]. Byulleten Eksperimental noi Biologii i Meditsiny 96, 14-16.
116. Miyazawa, M., Tsuji-Kawahara, S. & Kanari, Y. (2008). Host genetic factors that control immune responses to retrovirus infections. Vaccine 26, 2981-2996.
117. Hasenkrug, K.J. & Dittmer, U. (2007). Immune control and prevention of chronic Friend retrovirus infection. Frontiers in Bioscience 12, 1544-1551. (Pubitemid 46846852)
118. Karpas, A. (2004). Human retroviruses in leukaemia and AIDS: reflections on their discovery, biology and epidemiology. Biological Reviews of the Cambridge Philosophical Society 79, 911-933.
119. Spierings, D.C., de Vries, E.G., Vellenga, E., van den Heuvel, F.A., Koornstra, J.J., Wesseling, J., Hollema, H. & de Jong, S. (2004). Tissue distribution of the death ligand TRAIL and its receptors. Journal of Histochemistry & Cytochemistry 52, 821-831. (Pubitemid 38703137)
120. Balyasnikova, I.V., Yeomans, D.C., McDonald, T.B. & Danilov, S.M. (2002). Antibody-mediated lung endothelium targeting: in vivo model on primates. Gene Therapy 9, 282-290.
121. Pecher, G. & Finn, O.J. (1996). Induction of cellular immunity in chimpanzees to human tumor- associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus- immortalized autologous B cells. Proceedings of the National Academy of Sciences of the USA 93, 1699-1704. (Pubitemid 26075188)
122. Barratt-Boyes, S.M., Vlad, A. & Finn, O.J. (1999). Immunization of chimpanzees with tumor antigen MUCl mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clinical Cancer Research 5, 1918-1924. (Pubitemid 29334476)
123. Barratt-Boyes, S.M., Kao, H. & Finn, O.J. (1998). Chimpanzee dendritic cells derived in vitro from blood monocytes and pulsed with antigen elicit specific immune responses in vivo. Journal of Immunotherapy 21, 142-148. (Pubitemid 28141719)
124. Soares, M.M., Mehta, V. & Finn, O.J. (2001). Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1- transgenic mice with different potential for tumor rejection. Journal of Immunology 166, 6555-6563. (Pubitemid 32467194)
125. Abbenante, G. & Fairlie, D.P. (2005). Protease inhibitors in the clinic. Medicinal Chemistry 1, 71-104.
126. Qian, M., Bai, S.A., Brogdon, B., Wu, J.T., Liu, R.Q., Covington, M.B., Vaddi, K., Newton, R.C., Fossler, M.J., Garner, C.E., Deng, Y., Maduskuie, T., Trzaskos, J., Duan, J.J., Decicco, C.P. & Christ, D.D. (2007). Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3 {4-[2-methyl-4-quinolinyl methoxy] phenyl}-2- oxopyrrolidinyl)-N-hydroxy-4- methylpentanamide), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans. Drug Metabolism & Disposition 35, 1916-1925. (Pubitemid 47481587)
127. Harpprecht, J., Jonker, M., Podzuweit, H.G., Hansmann, M.L., Treumer, J., Eckstein, V., van Eerd, P.C. & Muller-Ruchholtz, W. (1990). Human monoclonal antibody Ha6D3, a candidate for treatment of leukaemia? In vitro reactivity of Ha6D3 with leukaemic cells and in vivo applications in a chimpanzee. British Journal of Cancer. Supplement 10, 44-47.
128. Sakurai, F. (2008). Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35. Biological & Pharmaceutical Bulletin 31, 1819-1825.
129. Sakurai, F., Kawabata, K. & Mizuguchi, H. (2007). Adenovirus vectors composed of subgroup B adenoviruses. Current Gene Therapy 7, 229-238. (Pubitemid 47232955)
130. Skog, J., Edlund, K., Bergenheim, A.T. & Wadell, G. (2007). Adenoviruses 16 and CV23 efficiently transduce human low-passage brain tumor and cancer stem cells. Molecular Therapy 15, 2140-2145. (Pubitemid 350148930)
131. Varnavski, A.N., Schlienger, K., Bergelson, J.M., Gao, G.P. & Wilson, J.M. (2003). Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector. Human Gene Therapy 14, 533-544. (Pubitemid 36438938)
132. Rinaldo, C.R. (2009). Dendritic cell-based human immunodeficiency virus vaccine. Journal of Internal Medicine 265, 138-158.
133. Duncan, C. & Roddie, H. (2008). Dendritic cell vaccines in acute leukaemia. Best Practice & Research. Clinical Haematology 21, 521-541.
134. Engell-Noerregaard, L., Hansen, T.H., Andersen, M.H., Thor Straten, P. & Svane, I.M. (2009). Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunology, Immunotherapy 58, 1-14.
135. de Gruijl, T.D., van den Eertwegh, A.J., Pinedo, H.M. & Scheper, R.J. (2008). Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunology, Immunotherapy 57, 1569-1577.
136. Koido, S., Hara, E., Homma, S., Fujise, K., Gong, J. & Tajiri, H. (2007). Dendritic/tumor fusion cell- based vaccination against cancer. Archivum Imm3 unologiae et Therapiae Experimentalis (Warsz) 55, 281-287.
137. Mosca, P.J., Lyerly, H.K., Clay, T.M., Morse, M.A. & Lyerly, H.K. (2007). Dendritic cell vaccines. Frontiers in Bioscience 12, 4050-4060.
138. Tacken, P.J., Torensma, R. & Figdor, C.G. (2006). Targeting antigens to dendritic cells in vivo. Immunobiology 211, 599-608. (Pubitemid 44241649)
139. Onaitis, M., Kalady, M.F., Pruitt, S. & Tyler, D.S. (2002). Dendritic cell gene therapy. Surgical Oncology Clinics of North America 11, 645-660.
140. Dutcher, J. (2002). Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park) 16, 4-10.
141. Schwartz, R.N., Stover, L. & Dutcher, J. (2002). Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 16, 11-20.
142. Shanafelt, A.B., Lin, Y., Shanafelt, M.C., Forte, C.P., Dubois-Stringfellow, N., Carter, C., Gibbons, J.A., Cheng, S.L., Delaria, K.A., Fleischer, R., Greve, J.M., Gundel, R., Harris, K., Kelly, R., Koh, B., Li, Y., Lantz, L., Mak, P., Neyer, L., Plym, M.J., Roczniak, S., Serban, D., Thrift, J., Tsuchiyama, L., Wetzel, M., Wong, M. & Zolotorev, A. (2000). A T- cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nature Biotechnology 18, 1197-1202. (Pubitemid 30823360)
143. Margolin, K., Atkins, M.B., Dutcher, J.P., Ernstoff, M.S., Smith 2nd, J.W., Clark, J.I., Baar, J., Sosman, J., Weber, J., Lathia, C., Brunetti, J., Cihon, F. & Schwartz, B. (2007). Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clinical Cancer Research 13, 3312-3319.
144. Ritter, G. & Livingston, P.O. (1991). Ganglioside antigens expressed by human cancer cells. Seminars in Cancer Biology 2, 401-409.
145. Stuhlmiller, G.M., Roberson, K.M. & Seigier, H.F. (1989). Serological response of non-human primates to human melanoma disialoganglioside GD3. Cancer Immunology, Immunotherapy 29, 205-210.
146. Chapman, P.B. (2003). Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Current Opinion in Investigational Drugs 4, 710-715.
147. Chapman, P.B., Williams, L., Salibi, N., Hwu, W.J., Krown, S.E. & Livingston, P.O. (2004). A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 22, 2904-2909. (Pubitemid 38900670)
148. Forero, A., Shah, J., Carlisle, R., Triozzi, P.L., LoBuglio, A.F., Wang, W.Q., Fujimori, M. & Conry, R.M. (2006). A phase I study of an anti-GD3
149. Chapman, P.B., Wu, D., Ragupathi, G., Lu, S., Williams, L., Hwu, W.J., Johnson, D. & Livingston, P.O. (2004). Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti- idiotypic monoclonal antibody that mimics GD3 ganglioside. Clinical Cancer Research 10, 4717-4723. (Pubitemid 38955522)
150. Seigler, H.F., Wallack, M.K., Vervaert, C.E., Bash, J.A., Roberson, K.M. & Stuhlmiller, G.M. (1989). Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies. Journal of Biological Response Modifiers 8, 37-52.
151. Spagnoli, G.C., Adamina, M., Bolli, M., Weber, W.P., Zajac, P., Marti, W., Oertli, D., Heberer, M. & Harder, F. (2005). Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation. World Journal of Surgery 29, 692-699. (Pubitemid 41187527)
152. Campoli, M.R., Chang, C.C., Kageshita, T., Wang, X., McCarthy, J.B. & Ferrone, S. (2004). Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Critical Reviews in Immunology 24, 267-296. (Pubitemid 40052428)
153. Hocker, T.L., Singh, M.K. & Tsao, H. (2008). Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. Journal of Investigative Dermatology 128, 2575-2595.
154. Fang, L., Lonsdorf, A.S. & Hwang, S.T. (2008). Immunotherapy for advanced melanoma. Journal of Investigative Dermatology 128, 2596-2605.
155. Muchmore, E.A. (2001). Chimpanzee models for human disease and immunobiology. Immunological Reviews 183, 86-93.
156. Chou, H.H., Takematsu, H., Diaz, S., Iber, J., Nickerson, E., Wright, K.L., Muchmore, E.A., Nelson, D.L., Warren, S.T. & Varki, A. (1998). A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proceedings of the National Academy of Sciences of the USA 95, 11,751-11,756.
157. Muchmore, E.A., Diaz, S. & Varki, A. (1998). A structural difference between the cell surfaces of humans and the great apes. American Journal of Physical Anthropology 107, 187-198. (Pubitemid 28460615)
158. Brinkman-Van der Linden, E.C., Sjoberg, E.R., Juneja, L.R., Crocker, P.R., Varki, N. & Varki, A. (2000). Loss of N-glycolylneuraminic acid in human evolution. Implications for sialic acid recognition by siglecs. Journal of Biological Chemistry 275, 8633-8640. (Pubitemid 30180213)
159. Gomaa, A.I., Khan, S.A., Toledano, M.B., Waked, I. & Taylor-Robinson, S.D. (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World Journal of Gastroenterology 14, 4300-4308.
160. Poduri, C.D. (2003). Hepatitis C virus (HCV) - a review molecular biology of the virus, immunodiagnostics, genomic heterogeneity and the role of virus in hepatocellular carcinoma. Indian Journal of Experimental Biology 41, 549-562.
161. Stuhlmiller, G.M. & Seigler, H.F. (1975). Characterization of a chimpanzee anti-human melanoma antiserum. Cancer Research 35, 2132-2137.
162. Leong, S.P., Hornung, M.O. & Krementz, E.T. (1976). Immunofluorescent studies on chimpanzee humoral responses to human melanoma cells. Oncology 33, 246-249.
163. Stuhlmiller, G.M. & Seigler, H.F. (1977). Enzymatic susceptibility and spontaneous release of human melanoma tumor-associated antigens. Journal of the National Cancer Institute 58, 215-221.
164. Adlercreutz, H., Musey, P.I., Fotsis, T., Bannwart, C., Wahala, K., Makela, T., Brunow, G. & Hase, T. (1986). Identification of lignans and phytoestrogens in urine of chimpanzees. Clinica Chimica Acta 158, 147-154. (Pubitemid 16030590)
165. Musey, P.I., Adlercreutz, H., Gould, K.G., Collins, D.C., Fotsis, T., Bannwart, C., Makela, T., Wahala, K., Brunow, G. & Hase, T. (1995). Effect of diet on lignans and isoflavonoid phytoestrogens in chimpanzees. Life Sciences 57, 655-664.
166. Wong, M.C., Emery, P.W., Preedy, V.R. & Wiseman, H. (2008). Health benefits of isoflavones in functional foods? Proteomic and metabonomic advances. Inflammopharmacology 16, 235-239.
167. Ward, H., Chapelais, G., Kuhnle, G.G., Luben, R., Khaw, K.T. & Bingham, S. (2008). Lack of prospective associations between plasma and urinary phytoestrogens and risk of prostate or colorectal cancer in the European Prospective into Cancer-Norfolk study. Cancer Epidemiology Biomarkers & Prevention 17, 2891-2894.
168. Anon. (2009). RxList Internet Drug Index. Available at: http://www.rxlist.com (Accessed 10.06.09). Atlanta, GA, USA: WebMD, Inc.
169. FDA (1998). Infliximab, Centocor Inc., Pharmacology Review. Available at: http://www.fda.gov/ downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/Approval Applications/ TherapeuticBiologicApplications/ ucm107706.pdf, 27pp. (Accessed 11.08.09).
170. Anon. (2009). RxList: Rituxan (Rituzimab). Available at: http://www.rxlist.com/rituxan-drug.htm (Accessed 11.08.09). Atlanta, GA, USA: WebMD, Inc.
171. Vugmeyster, Y., Howell, K., McKeever, K., Combs, D. & Canova-Davis, E. (2003). Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. International Immunopharmacology 3, 1477-1481. (Pubitemid 37025728)
172. Vugmeyster, Y. & Howell, K. (2004). Rituximab- mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. International Immunopharmacology 4, 1117-1124. (Pubitemid 38844187)
173. Vugmeyster, Y., Howell, K., Bakshl, A., Flores, C. & Canova-Davis, E. (2003). Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry A 52, 101-109. (Pubitemid 37521508)
174. Rubenstein, J.L., Combs, D., Rosenberg, J., Levy, A., McDermott, M., Damon, L., Ignoffo, R., Aldape, K., Shen, A., Lee, D., Grillo-Lopez, A. & Shuman, M.A. (2003). Rituximab therapy for CNS lym phomas: targeting the leptomeningeal compartment. Blood 101, 466-468. (Pubitemid 36077565)
175. 125I-labeled full-length and Fab anti- bodies in rhesus monkeys following intravitreal administration. Toxicologic Pathology 27, 536-544. (Pubitemid 29446822)
176. Anon. (2009). RxList: Trastuzumab (Herceptin). Available at: http://www.rxlist.com/herceptin-drug. htm (Accessed 10.06.09). Atlanta, GA, USA: WebMD, Inc.
177. Phan, D.T., Gidali, J., Feher, I., Harsanyi, V., Petranyi, G.G. & Hollan, S.R. (1987). Comparison of efficiency of complements from various species for T-cell depletion from Cercopithecus aethiops bone marrow with Campath-1 MoAb in vitro. Haematologia (Budapest) 20, 203-213.
178. Phan, D.T., Barta, E., Gidali, J., Feher, I., Hars, anyi, V., Petranyi, G.G. & Hollan, S.R. (1987). T- cell depletion of Cercopithecus aethiops monkey bone marrow with Campath-1 monoclonal anti- body and complement. Haematologia (Budapest) 20, 155-163.
179. Phan, D.T., Benczur, M., Gidali, J., Feher, I., Harsanyi, V., Nemes, L., Petranyi, G. & Hollan, S.R. (1989). Cercopithecus aethiops monkey as a reliable model for in vitro study of T cell depletion of bone marrow with Campath-1 plus complement. Folia Haematologica (Leipzig, Germany) 116, 97-106.
180. Hale, G., Swirsky, D.M., Hayhoe, F.G. & Waldmann, H. (1983). Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Molecular Biology & Medicine 1, 321-334.
181. Anon. (2009). RxList: Erbitux (Cetuximab). Available at: http://www.rxlist.com/erbitux-drug.htm (Accessed 10.06.09). Atlanta, GA, USA: WebMD, Inc.
182. Anon. (2009). RxList: Avastin (Bevacizumab). Available at: http://www.rxlist.com/avastin-drug. htm (Accessed 10.06.09). Atlanta, GA, USA: WebMD, Inc.
183. Xu, L., Zuch, C.L., Lin, Y.S., Modi, N.B. & Lum, B.L. (2008). Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys. Cancer Chemotherapy & Pharmacology 61, 607-614.
184. Gaudreault, J., Shiu, V., Bricarello, A., Christian, B.J., Zuch, C.L. & Mounho, B. (2005). Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics. International Journal of Toxicology 24, 357-363. (Pubitemid 41540959)
185. Gerber, H.P. & Ferrara, N. (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Research 65, 671-680.
186. Anon. (2009). RxList: Vectibix (Panitumumab). Available at: http://www.rxlist.com/vectibix-drug. htm (Accessed 10.06.09). Atlanta, GA, USA: WebMD, Inc.
187. Kuroki, M., Huang, J., Shibaguchi, H., Tanaka, T., Zhao, J., Luo, N., Hachimine, K., Kinugasa, T., Maekawa, S., Enatsu, S., Hamanaka, W., Fukami, T. & Kuroki, M. (2006). Possible applications of antibodies or their genes in cancer therapy. Anticancer Research 26, 4019-4025. (Pubitemid 46031546)
188. Schuster, M., Nechansky, A. & Kircheis, R. (2006). Cancer immunotherapy. Biotechnology Journal 1, 138-147.
189. Sharkey, R.M. & Goldenberg, D.M. (2006). Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA: Cancer Journal for Clinicians 56, 226-243.
190. Stern, M. & Herrmann, R. (2005). Overview of monoclonal antibodies in cancer therapy: present and promise. Critical Reviews in Oncology/ Hematology 54, 11-29. (Pubitemid 40387003)
191. Loisel, S., Ohresser, M., Pallardy, M., Dayde, D., Berthou, C., Cartron, G. & Watier, H. (2007). Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Critical Reviews in Oncology/Hematology 62, 34-42. (Pubitemid 46330797)
192. Keefe, D.L. (2002). Trastuzumab-associated cardiotoxicity. Cancer 95, 1592-1600.
193. + regulatory T cells. Autoimmunity Reviews 5, 40-45. (Pubitemid 41759441)
194. Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., Fox, B., Tarrant, G., Robinson, J., Meager, T., Dolman, C., Thorpe, S.J., Bristow, A., Wadhwa, M., Thorpe, R. & Poole, S. (2007). "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. Journal of Immunology 179, 3325-3331.
195. Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A., Brunner, M.D. & Panoskaltsis, N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New England Journal of Medicine 355, 1018-1028.
196. Chapman, K. (2006). Opportunities for reducing the use of non-human primates in the development of monoclonal antibodies - a workshop report, 30pp. Available at: http://www.nc3rs.org.uk/ downloaddoc.asp?id=515 (Accessed 11.08.09). London, UK National Centre for the Replacement, Refinement and Reduction of Animals in Research.
197. EMEA (2007). Remicade - European Public Assessment Report. Available at: http://www. emea.europa.eu/humandocs/Humans/EPAR/ remicade/remicade.htm (Accessed 10.06.09). London, UK: European Medicines Agency.
198. NEAVS (2009). Sanctuaries/Facilities. Available at: http://www. releasechimps.org/mission/provide- sanctuary/sanctuaries-facilities/ (Accessed 10.06. 09). Boston, MA, USA: New England Anti- Vivisection Society (Project R&R).
199. NCRR (undated). Chimpanzee Management Pro gram. Available at: http://www.ncrr.nih.gov/ comparative-medicine/chimpanzee-management- program/ (Accessed 10.06.09). Bethesda, MD, USA: National Center for Research Resources.
200. NEAVS (2009). EU Animal Testing Vote: One Step Forward and One Step Stuck. Available at: http:// www.releasechimps.org/2009/05/14/eu-animal- testing-vote-one-step-forward-and-one-step-stuck/ (Accessed 10.06.09). Boston, MA, USA: New England Anti-Vivisection Society (Project R&R).
201. Puente, X.S., Gutierrez-Fernandez, A., Ordonez, G.R., Hillier, L.W. & Lopez-Otin, C. (2005). Comparative genomic analysis of human and chimpanzee proteases. Genomics 86, 638-647. (Pubitemid 41752944)
202. Glazko, G., Veeramachaneni, V., Nei, M. & Makalowski, W. (2005). Eighty percent of proteins are different between humans and chimpanzees. Gene 346, 215-219.
203. Calarco, J.A., Xing, Y., Caceres, M., Calarco, J.P., Xiao, X., Pan, Q., Lee, C., Preuss, T.M. & Blencowe, B.J. (2007). Global analysis of alternative splicing differences between humans and chimpanzees. Genes & Development 21, 2963-2975.
204. Ahmed, J., Gunther, S., Moller, F. & Preissner, R. (2007). A structural genomics approach to the regulation of apoptosis: chimp vs. human. Genome Informatics 18, 22-34.
205. Varki, A. (2000). A chimpanzee genome project is a biomedical imperative. Genome Research 10, 1065-1070.
206. Miller, B.A., Scoppa, S.M. & Feuer, E.J. (2006). Racial/ethnic patterns in lifetime and age-conditional risk estimates for selected cancers. Cancer 106, 670-682.
207. Russell, W.M.S. & Burch, R.L. (1959). The Principles of Humane Experimental Technique, 238pp. London, UK: Methuen.